{
    "title": "Merck KGaA says MS drug has blockbuster potential; key data expected in December",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12648017/Merck-KGaA-says-MS-drug-blockbuster-potential-key-data-expected-December.html",
    "date": "2023-10-19",
    "keywords": [
        "drug",
        "trial",
        "burger",
        "ceo",
        "merck",
        "blockbuster",
        "damage",
        "race",
        "approval",
        "april",
        "company",
        "class",
        "garijo",
        "study",
        "btk",
        "candidate",
        "germanys",
        "kgaa",
        "companys",
        "sclerosis",
        "industry",
        "term",
        "type",
        "enrolment",
        "evobrutinib",
        "share",
        "price",
        "time",
        "food",
        "administration",
        "injury",
        "intervention",
        "ability",
        "status",
        "belen",
        "readout",
        "phase",
        "december",
        "process",
        "confidence",
        "benefitrisk",
        "capital",
        "day",
        "darmstadt",
        "headquarters",
        "thursday",
        "stage",
        "end",
        "year",
        "autoimmune",
        "reaction",
        "sanofi",
        "novartis",
        "liver",
        "remibrutinib",
        "roche",
        "inhibitor",
        "ms",
        "brain",
        "disease",
        "midstage",
        "safety",
        "reporting",
        "bill",
        "berkrot"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}